Cerebrolysin: Clinical Overview and the Cochrane Findings

Cerebrolysin, developed as FPF-1070, is a peptide preparation derived from porcine brain tissue, administered by injection and used in a number of European, Asian and Latin American countries for stroke, traumatic brain injury and dementia. It is not FDA-approved, and its evidence base has been assessed by systematic review more thoroughly than almost anything else in this formulary.

This guide situates Cerebrolysin within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What Cerebrolysin is

Cerebrolysin is produced by enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. It is not a single defined molecule but a complex preparation, which is a significant characterization limitation.

The proposed mechanism is neurotrophic: that the peptide fraction mimics the action of endogenous neurotrophic factors such as BDNF and NGF, supporting neuronal survival, synaptic plasticity and repair after injury. Preclinical work has reported neuroprotective effects in various models.

Because it is tissue-derived rather than synthetic, batch-to-batch consistency and the theoretical concerns attaching to animal-derived biologicals both apply.

What the systematic reviews concluded

Cerebrolysin has been the subject of Cochrane systematic reviews across its principal indications, and the findings have been consistent enough to be worth stating plainly.

For acute ischemic stroke, review of the randomized evidence concluded that Cerebrolysin did not show a benefit on death or dependency. Notably, the pooled analysis also identified a higher rate of serious adverse events in treated participants, a finding that argues against the assumption that an ineffective treatment is at least harmless.

For vascular dementia and related cognitive indications, reviews have generally found the evidence insufficient to support routine use, citing methodological limitations across the available trials.

Reviewers have also repeatedly noted concerns about publication bias and trial quality, with much of the positive literature originating from a limited set of centres and, in some cases, sponsor involvement.

This is a distinct evidentiary situation from most of this formulary. The problem is not an absence of trials — there are many. It is that when those trials are systematically appraised together, the benefit does not hold up.

Why it is used abroad but not approved here

Cerebrolysin is approved and marketed in numerous countries and is genuinely in routine clinical use in some of them. It has never been approved by the FDA, and it is not an established compounding substance in the United States.

This divergence is a useful case study. Different regulators apply different evidentiary standards and reach different conclusions, and a drug's availability in another country is not evidence of efficacy. Clinicians encountering patients who obtained Cerebrolysin abroad — which does happen — should understand that its use elsewhere does not reflect a favorable evidence base that the FDA overlooked.

The same caution applies in reverse to compounds such as PDRN, where international use is also ahead of US approval — but there the published evidence in the primary indication is stronger. The two situations are not equivalent, and distinguishing them requires reading the actual literature rather than counting approvals.

What to tell patients

Patients ask about Cerebrolysin after stroke, brain injury or in early cognitive decline — circumstances in which they are highly motivated and existing options are limited.

The accurate answer is that it has been tested extensively, that systematic review of those trials has not demonstrated benefit, and that pooled data raised a serious adverse event signal in stroke. That is a stronger and more useful statement than "not approved here."

For cognitive decline and stroke recovery, the interventions with genuine evidence — vascular risk factor management, structured rehabilitation, physical activity, and treatment of contributing conditions — deserve the emphasis.